Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | AGXT | P21549 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1972358 | 1.00 | TAAR1 (0.40) | TAAR1CYP2A6CYP1A2TP53TSHR | |
| SCHEMBL8346829 | 1.00 | TAAR1 (0.40) | TAAR1CYP2A6CYP1A2TP53TSHR | |
| SCHEMBL9503518 | 0.83 | CA2 (0.41) | TAAR1TP53TSHRCA2SLC6A2 | |
| SCHEMBL8855721 | 0.83 | TSHR (0.39) | TAAR1TP53TSHRCA1CA2 | |
| SCHEMBL2269394 | 0.81 | CYP3A4 (0.42) | TAAR1TP53TSHRCA1CA2 | |
| SCHEMBL242931 | 0.81 | CYP3A4 (0.42) | TAAR1TP53TSHRCA1CA2 | |
| SCHEMBL9498462 | 0.81 | CYP3A4 (0.42) | TAAR1TP53TSHRCA1CA2 | |
| SCHEMBL6670843 | 0.81 | HRH3 (0.48) | TAAR1CA1CA2CA9SLC6A2 | |
| SCHEMBL6670839 | 0.81 | HRH3 (0.48) | TAAR1CA1CA2CA9SLC6A2 | |
| SCHEMBL13334658 | 0.80 | TP53 (0.42) | TAAR1CYP2A6CYP1A2TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | claimed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | claimed |
| EP-1078002-B1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LAB (US) | 2008-05-21 | — | — | EP | claimed |
| US-20050124548-A1 | Peptide antiangiogenic drugs | HENKIN JACK (US) | 2005-06-09 | — | — | US | claimed |
| US-6777535-B1 | USEFUL FOR TREATING CONDITIONS WHICH ARISE OR ARE EXACERBATED BY ANGIOGENESIS | ABBOTT LABORATORIES | 2004-08-17 | — | — | US | claimed |
| US-6753408-B1 | DRUGS USED FOR THERAPY | ABBVIE INC. | 2004-06-22 | — | — | US | claimed |
| US-6716963-B1 | OLIGOPEPTIDES | ABBOTT LABORATORIES | 2004-04-06 | — | — | US | claimed |
| EP-1242455-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2002-09-25 | — | — | EP | claimed |
| EP-1232183-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2002-08-21 | — | — | EP | claimed |
| WO-2001038397-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | claimed |
| WO-2001038347-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | claimed |
| EP-1078002-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 2001-02-28 | — | — | EP | claimed |
| WO-1999061476-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 1999-12-02 | — | — | WO | claimed |
| US-5140009-A | Stable against proteolytic enzymes; anticarcinogenic agents; urogenital disorders | TAP PHARMACEUTICALS, INC. (US) | 1992-08-18 | — | — | US | claimed |
| EP-0413209-A1 | LHRH analogs | TAP Pharmaceuticals Inc. (US) | 1991-02-20 | — | — | EP | claimed |
| EP-0127899-B1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | The Administrators of The Tulane University Educational Fund (US) | 1987-10-21 | — | — | EP | claimed |
| EP-0145768-A1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | COY, David Howard (US) | 1985-06-26 | — | — | EP | claimed |
| WO-1984004916-A1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | COY DAVID HOWARD (US) | 1984-12-20 | — | — | WO | claimed |
| EP-0127899-A1 | Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith | The Administrators of The Tulane University Educational Fund (US) | 1984-12-12 | — | — | EP | claimed |
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | disclosed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | disclosed |
| EP-1078002-B1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LAB (US) | 2008-05-21 | — | — | EP | disclosed |
| US-7314879-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-7169777-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-20050124548-A1 | Peptide antiangiogenic drugs | HENKIN JACK (US) | 2005-06-09 | — | — | US | disclosed |
| US-6777535-B1 | USEFUL FOR TREATING CONDITIONS WHICH ARISE OR ARE EXACERBATED BY ANGIOGENESIS | ABBOTT LABORATORIES | 2004-08-17 | — | — | US | disclosed |
| US-6774211-B1 | Peptide antiangiogenic drugs | ABBOTT LABORATORIES | 2004-08-10 | — | — | US | disclosed |
| US-6753408-B1 | DRUGS USED FOR THERAPY | ABBVIE INC. | 2004-06-22 | — | — | US | disclosed |
| US-6716963-B1 | OLIGOPEPTIDES | ABBOTT LABORATORIES | 2004-04-06 | — | — | US | disclosed |
| EP-1242455-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2002-09-25 | — | — | EP | disclosed |
| EP-1232183-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001038347-A2 | PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | disclosed |
| WO-2001038397-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1078002-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999061476-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 1999-12-02 | — | — | WO | disclosed |
| US-5300492-A | Suppressing levels of sex hormones in male or female mammals | TAP PHARMACEUTICALS (US) | 1994-04-05 | — | — | US | disclosed |
| US-5110904-A | Luteinizing hormone releasing hormone; suppression of sex hormones | ABBOTT LABORATORIES (US) | 1992-05-05 | — | — | US | disclosed |
| EP-0413209-A1 | LHRH analogs | TAP Pharmaceuticals Inc. (US) | 1991-02-20 | — | — | EP | disclosed |
| EP-0127899-B1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | The Administrators of The Tulane University Educational Fund (US) | 1987-10-21 | — | — | EP | disclosed |
| EP-0145768-A1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | COY, David Howard (US) | 1985-06-26 | — | — | EP | disclosed |
| US-4505897-A | INCREASING RELEASE OF GROWTH HORMONE, INSULIN, AND GLUCAGON | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 1985-03-19 | — | — | US | disclosed |
| WO-1984004916-A1 | CYCLIC PENTAPEPTIDES DISPLAYING SOMATOSTATIN ANTAGONISM AND METHOD OF TREATMENT OF MAMMALS THEREWITH | COY DAVID HOWARD (US) | 1984-12-20 | — | — | WO | disclosed |
| EP-0127899-A1 | Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith | The Administrators of The Tulane University Educational Fund (US) | 1984-12-12 | — | — | EP | disclosed |
| EP-0127899-A1 | Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith | The Administrators of The Tulane University Educational Fund (US) | 1984-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | GNRHR, GRIN1, GRIN3A | TAAR1 478/4885CYP2A6 3402/4885CYP1A2 3674/4885 |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | GNRHR, GRIN1, GRIN3A | TAAR1 478/4885CYP2A6 3402/4885CYP1A2 3674/4885 |
| US-20050124548-A1 | Peptide antiangiogenic drugs | VEGFA, NPPA, FLT1 | TAAR1 3138/4885CYP2A6 1882/4885CYP1A2 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.